Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rhea-AI Summary

Rezolute (Nasdaq:RZLT) announced that its management team will participate in the BTIG Virtual Biotechnology Conference, held on July 28-29, 2026. Management will conduct one-on-one investor meetings, which can be scheduled through BTIG representatives. Rezolute focuses on treating refractory hypoglycemia from congenital or acquired hyperinsulinism and is developing the antibody therapy ersodetug, studied in clinical trials and real-world HI cases.

Market reaction after investor conference participation: RZLT +14.38% in the Jul 21 session

+14.38%

27 alerts

+14.38% Session close to close

+10.0% Peak in 4 hr 40 min

$443.91M Market Cap

0.4x Rel. Volume

In the Jul 21 session, RZLT gained 14.38%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.0% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +14.4% in the session following this news. Historical news ID 1066865 recorded a -1...

Analysis

The stock surged +14.4% in the session following this news. Historical news ID 1066865 recorded a -1.53% 24-hour reaction to another conference announcement. A strong positive response here would contrast with that precedent; moderate short positioning remained a sourced volatility risk.

Key Figures

Conference dates: July 28-29, 2026

1 metrics

Conference dates July 28-29, 2026 BTIG Virtual Biotechnology Conference

Historical Context

5 past events · Latest: Jun 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 17	Clinical data presentation	Positive	+4.8%	Endocrine Society presentations included tumor hyperinsulinism and Phase 3 clinical program data.
Jun 04	Conference presentation schedule	Neutral	-1.5%	Company announced four presentations at the upcoming Endocrine Society annual meeting.
Jun 02	Phase 3 clinical data	Positive	+10.8%	Interim upLIFT data showed six of eight participants met the primary endpoint.
May 12	Quarterly earnings report	Neutral	+0.9%	Fiscal third-quarter results included financial results and clinical program updates.
May 11	Investor conference participation	Neutral	-1.3%	Management announced participation in two upcoming investor conferences and fireside chats.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Conference announcements previously showed negative reactions, while clinical-data announcements were generally aligned with positive reactions.

Key Terms

hyperinsulinism, refractory hypoglycemia

2 terms

hyperinsulinism medical

"refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism"

Hyperinsulinism is a medical condition in which the body makes too much insulin, causing blood sugar to fall dangerously low. It matters to investors because drugs, devices, or tests that diagnose, manage, or correct this imbalance can lead to clinical trial milestones, regulatory approvals, patents and new sales—much like fixing a broken thermostat restores stable temperature, successful treatments can create significant market value.

refractory hypoglycemia medical

"focused on treating refractory hypoglycemia caused by a congenital or any acquired form"

A severe form of low blood sugar that does not correct with standard treatments such as oral glucose, intravenous dextrose, or routine medication adjustments; it is often caused by persistent underlying disease, certain drugs, or hormonal problems. For investors, it matters because it affects clinical trial results, product safety profiles, regulatory reviews, and potential liability or market demand—like a fire that keeps burning despite the usual hoses, prompting deeper fixes and scrutiny.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

FAQ

When will Rezolute (RZLT) participate in the BTIG Virtual Biotechnology Conference 2026?

Rezolute will participate in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. According to Rezolute, its management team will attend the virtual event and hold one-on-one investor meetings during the two conference days.

How can investors schedule one-on-one meetings with Rezolute (RZLT) at the BTIG Virtual Biotechnology Conference?

Investors can schedule one-on-one meetings with Rezolute management by contacting their BTIG representative. According to Rezolute, all investor meetings during the July 28-29, 2026 conference are arranged directly through BTIG’s channels.

What does Rezolute (RZLT) focus on in its biotechnology programs?

Rezolute focuses on treating refractory hypoglycemia caused by congenital or acquired hyperinsulinism (HI). According to Rezolute, it is a late-stage ultra-rare disease company dedicated to therapies for difficult-to-treat HI-related hypoglycemia.

What is Rezolute’s antibody therapy ersodetug and what is it being studied for?

Ersodetug is Rezolute’s antibody therapy for refractory hypoglycemia due to various causes of hyperinsulinism. According to Rezolute, ersodetug has been studied in clinical trials and used in real-world HI cases to address persistent low blood sugar.

Where can investors find more information about Rezolute (Nasdaq:RZLT) and its programs?

Investors can find more information about Rezolute and its HI programs at www.rezolutebio.com. According to Rezolute, the website provides details on its focus on refractory hypoglycemia, clinical work with ersodetug, and corporate contact information.